SALACUNAR

This multicenter clinical trial assesses whether a polyphenol-rich Salicornia extract effectively slows the progression of cognitive impairment in patients who have experienced lacunar infarcts, comparing this intervention against standard clinical practice.

SALACUNAR (LACI-2-polyphenols): a multicenter randomized clinical trial comparing a polyphenol-rich Salicornia extract with usual clinical practice to assess its efficacy on progression of cognitive impairment in a cohort of patients with lacunar infarcts.

Sponsor: HVM-HVR-IBIS

Phase: IV

Status: Recruiting

View clinical trials catalogue

Public study eligibility criteria

Inclusion

  • \- Patients with lacunar ischemic stroke, confirmed by cranial magnetic resonance imaging performed within the year prior to inclusion, who have an mRS of 3 or less at the time of inclusion will be included (independent patients or those who require assistance with walking). The inclusion age will be between 40 and 90 years.

Exclusion

  • * Consumption of vitamin supplements or polyphenol supplements within 30 days prior to inclusion
  • * Hyperthyroidism
  • * mRS \>3, serious illness, or expected life expectancy \<12 months
  • * Dysphagia preventing intake of the study capsules
  • * Allergies or intolerance to halophytes
  • * Pregnant or breastfeeding
  • * Active neoplasia
  • * Participation in another study